NovoCure Q2 Revenue Jumps 16%, Adjusted EBITDA Turns Positive, but TRIDENT Trial Misses Primary Endpoint

summarizeSummary

NovoCure's Q2 2026 revenue grew 16% to $183.6M, Adjusted EBITDA turned positive at $10.8M, and the Optune Pax launch added 285 patients. However, the Phase 3 TRIDENT trial in GBM failed to meet its primary endpoint, removing a major growth driver.

check_boxKey Events · Earnings and Guidance · NVCR

• Revenue Growth Accelerates

  Q2 2026 net revenues rose 16% YoY to $183.6M, driven by 18% active patient growth to 5,128. U.S. revenue grew 9% to $103.0M, while international markets surged 25% to $74.7M.

• Adjusted EBITDA Turns Positive

  Adjusted EBITDA swung to a gain of $10.8M from a loss of $9.9M in Q2 2025, reflecting revenue growth, cost efficiencies, and a $4.9M tariff refund. Net loss narrowed to $15.7M from $40.1M.

• TRIDENT Trial Misses Primary Endpoint

  The Phase 3 TRIDENT trial evaluating earlier initiation of TTFields therapy in newly diagnosed GBM failed to show a statistically significant improvement in overall survival (median OS 17.7 vs 17.5 months, HR 0.953, p=0.519).

• Optune Pax Launch Gains Traction

  Optune Pax for pancreatic cancer contributed $1.6M in revenue and 285 active patients in its first full quarter post-FDA approval. The company also received CE Mark approval for the same indication.

auto_awesomeAnalysis · NVCR · Industrial Applications And Services

NovoCure delivered strong commercial execution with 18% active patient growth and a swing to positive Adjusted EBITDA, but the Phase 3 TRIDENT trial failure in newly diagnosed GBM removes a key near-term catalyst. The Optune Pax launch is off to a promising start with 285 active patients and $1.6M in revenue. Cash remains robust at $440.6M, though the company acknowledges it may need to raise additional capital as it expands into new indications. The mixed quarter — operational momentum offset by a clinical setback — keeps the investment thesis in flux.